Mdxhealth S.A. (MDXH)
NASDAQ:MDXH
Want to see MDXH full AI Analyst Report?
MDXH Stock Chart & Stats
$2.31
-$0.10(-4.55%)
At close: 4:00 PM EST
$2.31
-$0.10(-4.55%)
Day’s Range― - ―
52-Week Range$0.51 - $5.33
Previous CloseN/A
Volume27.23K
Average Volume (3M)1.07M
Market Cap
$30.15M
Enterprise Value$105.11M
Total Cash (Recent Filing)$29.03M
Total Debt (Recent Filing)$95.11M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Aug 13, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding51,364,520
10 Day Avg. Volume843,957
30 Day Avg. Volume1,074,688
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)-14.77
Price to Sales (P/S)1.66
P/FCF Ratio-15.43
Enterprise Value/Market Cap3.49
Enterprise Value/Revenue1.29
Enterprise Value/Gross Profit2.24
Enterprise Value/Ebitda-17.61
Forecast
1Y Price Target
$3.38Price Target Upside46.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.64
Revenue Forecast (FY)$116.15M
Bulls Say, Bears Say
Bulls Say
Revenue Scaling & Strong Gross MarginsSustained multi-year top-line growth and ~60% gross margins indicate durable unit economics and commercial traction in prostate diagnostics. Strong margins provide room to absorb SG&A while scaling, improving the odds of reaching operating profitability as revenue grows and integration synergies materialize.
Commercial Integration And Sales ExecutionSuccessful migration and cross-training of sales reps create a more focused, efficient commercial organization that can sell a broader prostate portfolio. This structural improvement should raise organic sell-through, lower per-test selling costs, and support sustainable volume growth over the next several quarters.
AI & Clinical Innovation InitiativesBuilding an AI data platform and embedding AI in clinical trials can strengthen product differentiation and improve prognostic performance. These capabilities are structural: they can raise clinical adoption, support stronger evidence for payors, and create a higher barrier to entry versus competitors over time.
Bears Say
Deteriorated Capital Structure (negative Equity)Negative equity and a material increase in debt materially weaken financial flexibility and heighten refinancing and covenant risk. This structural imbalance constrains the company's ability to fund commercialization, R&D, or trials without dilutive financing or costly borrowing over the coming 2–6 months.
Persistent Negative Operating & Free Cash FlowOngoing cash burn means the business is not yet self-funding and will rely on external capital or asset sales. After paying a $15M earn-out and with cash reduced pro forma, continued negative FCF limits runway for investments and raises dilution and liquidity risk in the medium term.
Medicare Recoupment & Resolve Exit RisksA contested recoupment exposure and the strategic exit of Resolve create regulatory, cash, and execution risks. Potential liability up to $10.4M, restructuring charges, and lost diversification from Resolve weaken resilience to reimbursement shifts and may strain payer relationships long term.
MDxHealth News
MDXH FAQ
What was Mdxhealth S.A.’s price range in the past 12 months?
Mdxhealth S.A. lowest stock price was $0.51 and its highest was $5.33 in the past 12 months.
What is Mdxhealth S.A.’s market cap?
Mdxhealth S.A.’s market cap is $30.15M.
When is Mdxhealth S.A.’s upcoming earnings report date?
Mdxhealth S.A.’s upcoming earnings report date is Aug 13, 2026 which is in 61 days.
How were Mdxhealth S.A.’s earnings last quarter?
Mdxhealth S.A. released its earnings results on May 13, 2026. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.145 by -$0.045.
Is Mdxhealth S.A. overvalued?
According to Wall Street analysts Mdxhealth S.A.’s price is currently Undervalued.
Does Mdxhealth S.A. pay dividends?
Mdxhealth S.A. does not currently pay dividends.
What is Mdxhealth S.A.’s EPS estimate?
Mdxhealth S.A.’s EPS estimate is -0.19.
How many shares outstanding does Mdxhealth S.A. have?
Mdxhealth S.A. has 51,364,520 shares outstanding.
What happened to Mdxhealth S.A.’s price movement after its last earnings report?
Mdxhealth S.A. reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.145. Following the earnings report the stock price went down -49.538%.
Which hedge fund is a major shareholder of Mdxhealth S.A.?
Currently, no hedge funds are holding shares in MDXH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MDxHealth Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.38 (46.10% Upside)
$3.38 (46.10% Upside)
Blogger Sentiment
Bullish
MDXH Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 22.3%
Last 30 Days ▲ 22.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.96%
12-Months-Change
Fundamentals
Return on Equity
402.97%
Trailing 12-Months
Asset Growth
-8.01%
Trailing 12-Months
Company Description
Mdxhealth S.A.
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
MDXH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed but cautiously positive outlook: operationally the company is refocusing on its high-growth prostate cancer franchise with clear commercial integration wins (ExoDx transition, sales cross-training), AI initiatives, and a raised 2026 revenue target implying 20–26% growth. However, material near-term headwinds exist — most notably the strategic exit of the Resolve UTI business, a Novitas recoupment notice up to $10.4M, pro forma margin compression, and a wider operating loss driven by the ExoDx acquisition and integration — all of which create execution and liquidity considerations in the short term. Overall, management frames the Resolve exit as a proactive, value-accretive repositioning to prioritize scalable core growth while defending against payer recoupment risk.View all MDXH earnings summariesMDXH Stock 12 Month Forecast
Average Price Target
$3.38
▲(46.10% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.45% Mutual Funds
20.13% Other Institutional Investors
78.23% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---